Rocket Lab’s $2.2 Billion Backlog Can’t Stop the Bleeding — But Institutions Are Buying the Dip
Published on 07/30/2026 at 00:50 | Redaktion boerse-global.de
The numbers tell two entirely different stories about Rocket Lab right now, and reconciling them is the challenge facing every investor in the stock. On one hand, the company just locked in the largest launch contract in its history — a $266 million deal with the US Space Force for up to 18 suborbital missions. Its total backlog stands at $2.2 billion. On the other hand, the share price has been cut nearly in half since May, falling from a high of €133.80 to the current €53.60, a decline of roughly 60 percent.
That kind of divergence between operational momentum and market sentiment is rare, and it has created a deeply polarized debate about what Rocket Lab is actually worth.
The sell-off has been brutal by any measure. Over the past 30 days alone, the stock has shed 37.67 percent of its value. The seven-day stretch ending with the latest close saw another 9 percent shaved off, and the year-to-date figure now stands at a 12.85 percent decline. Technical indicators reflect the damage: the 14-day relative strength index has fallen to 30.8, deep into oversold territory. The annualized 30-day volatility sits at roughly 89 percent, making this one of the more punishing rides in the space sector.
Yet for all the red on the screen, the long-term picture remains strikingly positive. On a 12-month basis, Rocket Lab shares are still up 41.05 percent. The stock was trading at €32.60 as recently as last November, meaning the current price represents a significantly higher floor than the one established just eight months ago.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Institutional investors see opportunity where retail sees panic
The most telling signal of the current disconnect is who is buying and who is selling. While retail traders appear to be exiting in droves, large institutional players have been quietly accumulating shares. Cathie Wood’s ARK Invest added roughly $4 million worth of Rocket Lab stock during the July weakness, and the Bank of Nova Scotia increased its position by 149.8 percent in the first quarter. These are not the actions of investors who believe the company is in trouble.
The insider selling narrative that has spooked some market participants deserves closer scrutiny. CEO Peter Beck sold shares worth approximately $286.4 million in early July, a transaction that some observers interpreted as a lack of confidence. But the sales were executed through a Rule 10b5-1 trading plan established by the Equatorial Trust on March 27 — months before the stock began its slide. The plan was designed for routine financial planning and portfolio diversification, not as a bet against the company’s prospects. Treating it as a warning signal conflates automated technical selling with a deliberate management signal.
The Space Force deal and the Neutron catalyst
The $266 million contract with the US Space Force is the headline operational achievement. The deal covers up to 18 suborbital launches using Rocket Lab’s HASTE platform for missile defense testing, securing revenue streams that extend through the end of the decade. It deepens the company’s already significant relationship with the US government and provides a contractual backbone that short-term traders tend to overlook.
Beyond that, the company is pushing hard toward the first flight of its Neutron rocket, a medium-to-heavy lift vehicle that represents the next major growth inflection point. The launch remains on track for the fourth quarter of 2026. Rocket Lab has also been advancing its vertical integration strategy, acquiring Motiv Space Systems — now rebranded as Rocket Lab Robotics — and developing the “Hungry Hippo” fairing design for Neutron. These moves are designed to improve gross margins, which stood at 26.6 percent in 2024.
A separate regulatory development could provide a structural tailwind for the entire industry. The Trump administration has proposed a reform that would allow the Federal Aviation Administration to waive environmental reviews for commercial rocket launches under multiple federal statutes. Less bureaucratic friction means a higher launch cadence, and for a company building a new rocket, that kind of regulatory clarity is invaluable.
The cash burn question
The biggest weight on the stock remains the capital intensity of the Neutron development program. Rocket Lab posted negative free cash flow of $321.8 million in 2025, a direct consequence of heavy infrastructure spending. Analysts project the company could turn cash-flow positive by 2027, but that timeline depends on Neutron reaching operational status without major delays or cost overruns.
The market capitalization now stands at roughly €35.11 billion, a figure that positions Rocket Lab firmly in the ranks of serious industrial companies rather than speculative penny stocks. The average analyst price target is €100.40, implying upside of about 87 percent from current levels. A separate consensus puts the target at €100.52, offering a similar margin of appreciation.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
A correction, not a collapse
The distinction that matters most for long-term holders is whether the current drawdown reflects a structural problem or merely the unwinding of speculative excess built up during the May rally. The company’s ability to execute high-pressure missions — such as “Victus Haze,” which launched a satellite with less than 24 hours’ notice — suggests operational competence is not the issue.
What the market is pricing in, instead, appears to be a combination of technical damage, volatility fatigue, and the natural cooling that follows a parabolic run. The stock has fallen below key moving averages, and the chart pattern looks ugly by any technical standard. But the fundamental thesis — a growing backlog, deepening government ties, a next-generation rocket nearing the launch pad, and institutional buyers stepping in during weakness — remains intact.
For patient capital, the question is not whether Rocket Lab will survive the current turbulence. It is whether the gap between a €53.60 share price and a $2.2 billion order book represents a buying opportunity or a value trap. The institutions placing bets on the former are betting that the industrial reality will eventually win out over the chart-based narrative.
Ad
Rocket Lab Stock: New Analysis - 30 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
